176 related articles for article (PubMed ID: 34429303)
21. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract][Full Text] [Related]
22. Congenital mesoblastic nephroma is characterised by kinase mutations including EGFR internal tandem duplications, the ETV6-NTRK3 fusion, and the rare KLHL7-BRAF fusion.
Zhao M; Yin M; Kuick CH; Chen H; Aw SJ; Merchant K; Ng EHQ; Gunaratne S; Loh AHP; Gu W; Tang H; Chang KTE
Histopathology; 2020 Oct; 77(4):611-621. PubMed ID: 32590884
[TBL] [Abstract][Full Text] [Related]
23. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
[TBL] [Abstract][Full Text] [Related]
24. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
Subbiah V; Gouda MA; Iorgulescu JB; Dadu R; Patel K; Sherman S; Cabanillas M; Hu M; Castellanos LE; Amini B; Meric-Bernstam F; Shen T; Wu J
NPJ Precis Oncol; 2024 Mar; 8(1):62. PubMed ID: 38438731
[TBL] [Abstract][Full Text] [Related]
25. ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors.
Alassiri AH; Ali RH; Shen Y; Lum A; Strahlendorf C; Deyell R; Rassekh R; Sorensen PH; Laskin J; Marra M; Yip S; Lee CH; Ng TL
Am J Surg Pathol; 2016 Aug; 40(8):1051-61. PubMed ID: 27259007
[TBL] [Abstract][Full Text] [Related]
26. Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors.
Davis JL; Lockwood CM; Stohr B; Boecking C; Al-Ibraheemi A; DuBois SG; Vargas SO; Black JO; Cox MC; Luquette M; Turpin B; Szabo S; Laetsch TW; Albert CM; Parham DM; Hawkins DS; Rudzinski ER
Am J Surg Pathol; 2019 Apr; 43(4):435-445. PubMed ID: 30585824
[TBL] [Abstract][Full Text] [Related]
27. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
[TBL] [Abstract][Full Text] [Related]
28. Sporadic pediatric papillary thyroid carcinoma harboring the ETV6/NTRK3 fusion oncogene in a 7-year-old Japanese girl: a case report and review of literature.
Otsubo R; Mussazhanova Z; Akazawa Y; Sato A; Matsuda K; Matsumoto M; Yano H; Matsuse M; Mitsutake N; Ando T; Niino D; Nagayasu T; Nakashima M
J Pediatr Endocrinol Metab; 2018 Mar; 31(4):461-467. PubMed ID: 29427554
[TBL] [Abstract][Full Text] [Related]
29. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
[TBL] [Abstract][Full Text] [Related]
30. ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.
Gao L; Ai X; Lu S
Lung Cancer; 2024 Jan; 187():107443. PubMed ID: 38113652
[TBL] [Abstract][Full Text] [Related]
31. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.
Rubin BP; Chen CJ; Morgan TW; Xiao S; Grier HE; Kozakewich HP; Perez-Atayde AR; Fletcher JA
Am J Pathol; 1998 Nov; 153(5):1451-8. PubMed ID: 9811336
[TBL] [Abstract][Full Text] [Related]
32. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
[TBL] [Abstract][Full Text] [Related]
33. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
34. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
35. Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima.
Iyama K; Matsuse M; Mitsutake N; Rogounovitch T; Saenko V; Suzuki K; Ashizawa M; Ookouchi C; Suzuki S; Mizunuma H; Fukushima T; Suzuki S; Yamashita S
Thyroid; 2017 Jun; 27(6):811-818. PubMed ID: 28351223
[TBL] [Abstract][Full Text] [Related]
36. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.
Bourgeois JM; Knezevich SR; Mathers JA; Sorensen PH
Am J Surg Pathol; 2000 Jul; 24(7):937-46. PubMed ID: 10895816
[TBL] [Abstract][Full Text] [Related]
37.
Bastos AU; de Jesus AC; Cerutti JM
Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
[TBL] [Abstract][Full Text] [Related]
38. Analysis of
Okamura R; Boichard A; Kato S; Sicklick JK; Bazhenova L; Kurzrock R
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30637364
[TBL] [Abstract][Full Text] [Related]
39. Post-HSCT Maintenance Treatment Using Entrectinib for an AML Patient Accompanied with ETV6::NTRK3: A Case Report.
Zhao X; Hao M; Zhang X; Wei J; Feng S; He Y; Jiang E; Han M
Onco Targets Ther; 2023; 16():1055-1059. PubMed ID: 38144903
[TBL] [Abstract][Full Text] [Related]
40. Myxoid spindle cell sarcoma with ETV6-NTRK3 fusion.
Kyriazoglou A; Dimitriadis E; Mahaira L; Kotsantis J; Kouloulias V; Kontogeorgakos V; Psyrri A; Agrogiannis G
Cancer Genet; 2022 Nov; 268-269():93-96. PubMed ID: 36274330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
